Please assess the completion status of the following clinical trial:

Trial Title: Dobutamine Versus Placebo for Low Superior Vena Cava Flow in Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Newborn infants born at ≤ 28 weeks of gestational age.~* Newborn infants born at \> 28 weeks of gestational age and ≤ 30 weeks of gestational age with moderate-severe respiratory distress syndrome, defined as the necessity of respiratory support with a mean pressure ≥ 4 cm H2O or FiO2 ≥ 0.3~* Admission at the NICU in the first 6 hours of life~* Inotrope treatment absent~* Inform consent signed~Exclusion criteria~* Early systemic hypotension, defined as a mean arterial pressure (MAP) lower than the gestational age, during at least 60 minutes and maintained after volume infusion~* Major congenital malformation~* Informed consent declined

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Hours
- Healthy Volunteers: f

Study Arms:
- Dobutamine (Type: EXPERIMENTAL): Patients with low SVCF in the first 12 hours of life will be randomised to receive dobutamine or placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).